Enhabit’s (EHAB) Hold Rating Reiterated at TD Cowen

Enhabit (NYSE:EHAB)‘s stock had its “hold” rating restated by research analysts at TD Cowen in a research note issued on Friday. They presently have a $13.80 target price on the stock. TD Cowen’s target price suggests a potential upside of 1.40% from the company’s previous close.

Several other research analysts also recently weighed in on EHAB. Leerink Partners upped their target price on Enhabit from $9.50 to $13.80 and gave the stock a “market perform” rating in a research note on Monday, February 23rd. Wolfe Research set a $12.00 price target on shares of Enhabit in a report on Thursday, January 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Enhabit in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft upgraded shares of Enhabit to a “buy” rating in a research report on Tuesday, January 13th. Finally, Jefferies Financial Group downgraded shares of Enhabit from a “buy” rating to a “hold” rating and upped their price target for the stock from $12.50 to $13.80 in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.57.

Enhabit Stock Performance

EHAB stock opened at $13.61 on Friday. Enhabit has a 52-week low of $6.47 and a 52-week high of $13.64. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.75. The firm has a market cap of $688.76 million, a P/E ratio of -151.22 and a beta of 1.56. The company’s 50-day simple moving average is $11.05 and its 200-day simple moving average is $9.33.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. The firm had revenue of $270.40 million during the quarter, compared to analyst estimates of $270.56 million. Enhabit had a positive return on equity of 4.67% and a negative net margin of 0.43%. As a group, equities analysts forecast that Enhabit will post 0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Enhabit

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC grew its stake in Enhabit by 48.9% during the 4th quarter. Corient Private Wealth LLC now owns 14,942 shares of the company’s stock valued at $138,000 after acquiring an additional 4,908 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Enhabit by 11.1% during the 4th quarter. Empowered Funds LLC now owns 262,221 shares of the company’s stock worth $2,418,000 after purchasing an additional 26,287 shares during the last quarter. Polymer Capital Management US LLC purchased a new stake in shares of Enhabit in the fourth quarter valued at approximately $169,000. Eversept Partners LP acquired a new stake in shares of Enhabit in the fourth quarter valued at approximately $2,015,000. Finally, Abel Hall LLC purchased a new position in Enhabit during the fourth quarter worth approximately $143,000.

About Enhabit

Enhabit, Inc (NYSE: EHAB) is a national provider of home-based healthcare services, offering a continuum of care designed to support patients in the comfort of their own homes. The company’s core mission is to deliver personalized clinical and non-clinical services that help individuals recover from illness or injury, manage chronic conditions, and, when necessary, receive compassionate end-of-life care. Enhabit’s business model centers on combining skilled clinical care with patient-centric service coordination to optimize outcomes and enhance the overall care experience.

The company’s service portfolio includes skilled nursing, physical, occupational and speech therapies, personal care assistance, palliative care and hospice services.